TitleImmunotherapy and Biomarkers in Neurodegenerative Disorders [electronic resource] / edited by Martin Ingelsson, Lars Lannfelt
ImprintNew York, NY : Springer New York : Imprint: Humana Press, 2016
Connect tohttp://dx.doi.org/10.1007/978-1-4939-3560-4
Descript X, 289 p. 40 illus., 32 illus. in color. online resource

SUMMARY

This practical volume examines a number of topics that explore the current status of immunotherapy and diagnostic markers for neurodegenerative disorders. With a focus on Alzheimer’s disease, the first sections of the book examine immunotherapeutic approaches for the aforementioned disease as well as for Parkinson’s disease and Huntington’s disease, amongst others. The last section of the book covers the importance of biomarker techniques to catch these diseases early enough for the treatments to be most useful. Written for the Methods in Pharmacology and Toxicology series, this book contains the kind of detailed descriptions and implementation advice that will offer a smooth transition into the lab. Authoritative and useful, Immunotherapy and Biomarkers in Neurodegenerative Disorders aims to aid in the continued progress in the development of novel immune-based drugs and diagnostic tools for these devastating brain diseases


CONTENT

Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overview -- Active Immunization Against the Amyloid-β Peptide -- Immunotherapy Against N-Truncated Amyloid-β Oligomers -- Immunotherapy Against Amyloid-β Protofibrils: Opportunities and Challenges -- Immunotherapy Against α-Synuclein Pathology -- Extracellular α-Synuclein as a Target for Immunotherapy -- Immunotherapy of Parkinson’s Disease -- Tau Immunotherapy -- Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms -- Immunotherapy on Experimental Models for Huntington’s Disease -- Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease -- Volumetric MRI as a Diagnostic Tool in Alzheimer's Disease -- PET Imaging as a Diagnostic Tool in Alzheimeŕs Disease -- Αlpha-Synuclein as a Diagnostic Biomarker for Parkinson’s Disease -- Imaging as a Diagnostic Tool in Parkinson’s Disease -- Mass Spectrometry-Based Proteomics in Biomarker Discovery for Neurodegenerative Diseases


SUBJECT

  1. Medicine
  2. Pharmacology
  3. Biomedicine
  4. Pharmacology/Toxicology